Stock Ratings / Health Care / ATYR / earnings

BCDA (49) DYAI (33) PASG (51) PLUR (39) ⌘ Pro Terminal →

aTyr Pharma Inc. (ATYR) Next Earnings Date & Expected ±12.5% Move

$5.37 +4.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.40

aTyr Pharma Inc. (ATYR) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $13.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.40 (+0.63%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATYR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY ATYR SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (30% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 92 (OVERBOUGHT (>70))

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.28-35.7% Next Q

Q2 (-2Q)

Grade E$0.18-5.6% Next Q

Q3 (-1Q)

Grade D$0.17+3058.8% Next Q

Current

Grade D$5.37-6.5% Hist 90D α

Trajectory: E (36) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATYR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATYR currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.44) and Max Pain ($5.64) forces dealer call-delta covering toward $46.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATYR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATYR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.67 Expected Swing

MODEL EARNINGS SETUP GAUGE

ATYR Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $4.25 • YoY Revenue Growth: -19.1%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$190.0K	-$74.1M	-$62.1M	52%
FY 2024	2024-12-31	$235.0K	-$64.0M	-$69.2M	52%
FY 2023	2023-12-31	$353.0K	-$50.4M	-$33.2M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATYR)

✓Walkthrough of ATYR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATYR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +562.96%▲ RESISTANCE BREAKOUT

2026-10-30O $5.32H $5.43L $4.32C $5.37VOL 120.2K

RES: $0.41SUP: $0.46SMA50: $0.44SMA200: $0.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATYR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATYR Butterfly Map → + Track ATYR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -19.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATYR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATYR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATYR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATYR)

Health Care Rank #522 of 1016 ⚔️ BCDA vs ATYR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATYR vs. BCDA, DYAI, PASG, PLUR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, aTyr Pharma Inc. (ATYR) ranks #522 by composite RQD confidence (44/100, grade D) and #866 by equity capitalization ($13.5M). Within this direct 5-issuer industry benchmark cohort, ATYR leads on earnings valuation at N/A trailing P/E, while ATYR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PASG currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with ATYR at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATYR ACTIVE aTyr Pharma Inc.	D	44/100	—	—	-35.0%	+4.56%	$13.5M	Benchmark Subject
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-atyr →
DYAI Dyadic International Inc.	E	33/100	—	24.9%	-35.0%	-8.40%	$14.5M	/dyai-vs-atyr →
PASG Passage Bio Inc.	D	51/100	—	—	-35.0%	+5.71%	$11.3M	/pasg-vs-atyr →
PLUR Pluri Inc.	D-	39/100	—	49.0%	-35.0%	-2.44%	$16.1M	/plur-vs-atyr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001339970

In its most recent audited fiscal period (FY2025, filed 2025-12-31), aTyr Pharma Inc. (ATYR) reported GAAP revenue of $190.0K (-19.1% vs. FY2024 revenue of $235.0K , and -46.2% cumulative change since FY2023) , GAAP net income of -$74.1M, operating cash flow of -$62.0M, and free cash flow of -$62.1M (+10.3% YoY). On the balance sheet, ATYR closed FY2025 with $93.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$190.0K	-$74.1M	-$62.0M	-$62.1M	$93.0M	—
FY2024 (FY)	2024-12-31	$235.0K	-$64.0M	-$69.1M	-$69.2M	$96.8M	—
FY2023 (FY)	2023-12-31	$353.0K	-$50.4M	-$33.2M	-$33.2M	—	—

3. ATYR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATYR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, aTyr Pharma Inc. (NASDAQ: ATYR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.37 (+4.56% 1D, market cap $13.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ATYR ranks #522 in composite RQD confidence.

How does ATYR compare to BCDA and DYAI in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATYR carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCDA (BioCardia Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $14.0M) and DYAI (Dyadic International Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $14.5M). Among the 5-stock peer group, ATYR leads on earnings multiple (N/A) while ATYR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATYR?

Per ATYR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339970), aTyr Pharma Inc. generated $190.0K in revenue (-19.1% YoY), -$74.1M in net income, and -$62.1M in free cash flow against $93.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATYR trading relative to its 50-day, 200-day, and 52-week technical levels?

ATYR last traded at $5.37 (+4.56% on volume of 238,737 shares), positioning the stock +1120.45% above its 50-day simple moving average ($0.44) and +752.38% above its 200-day simple moving average ($0.63). Across its 52-week range of $4.08 to $44.40, ATYR sits at the 3.2% percentile with a 14-day RSI of 97.3 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($4.70 to $6.04).

ATYR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ATYR's next earnings date?

Based on SEC filing cadence, aTyr Pharma Inc. (ATYR)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ATYR stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ATYR, spanning a range between $4.7 and $6.04.

Direct Sub-Reports: ATYR RQD Cockpit ATYR 12M Forecast ATYR Earnings & Move ATYR Dividends & DRIP ATYR Insiders & 13F ATYR Whale Options ATYR Profit Sankey ATYR News & Why